Streifeneder ortho.production GmbH is an internationally active developer and supplier of orthopedic mobility solutions based in Emmering near Munich. The company manufactures and distributes prosthetic and orthotic components, orthopedic materials, and workshop and supply technology; it positions itself as a full-range supplier and regularly exhibits at trade shows. In 2024, approximately 100 employees generated around €25 million in revenue; about 70% of this revenue comes from prosthetics and materials. The majority of revenue is generated in Germany, and Streifeneder also supplies customers in other European markets as well as in the Americas and the APAC region. The company is part of the Streifeneder Group (F. G. Streifeneder KG), which also operates a network of O&P service locations.
With this transaction, Embla aims to expand its offering toward a full product range for a larger portion of the global O&P market and strengthen its presence in Germany—the second-largest O&P market. The closing is subject to antitrust approvals; the proceedings are pending with the German Federal Cartel Office under file number B3-70/25. The financing is structured as a contribution in kind: Upon closing, 2,805,135 new Embla shares are to be issued at DKK 33.26 per share (total value of approximately DKK 93 million or approximately €12.5 million); the selling shareholders will subscribe to all new shares and are subject to a two-year lock-up. Embla does not expect any material impact on its 2025 forecast. Embla is a global provider of mobility solutions (prosthetics, neuro-orthotics, bracing & supports) with over 4,000 employees and brands such as Össur, College Park, and FIOR & GENTZ; it emerged in 2024 from the rebranding of Össur hf. to the new parent organization; the operating brands remain in place. Additionally, Embla has joined the UN Global Compact, supports the UN Sustainable Development Goals, and has SBTi-validated climate targets.
ConAlliance is one of the leading M&A advisory firms in the healthcare sector and provides comprehensive support to companies throughout acquisition and divestiture processes. Since its founding, the firm has successfully executed more than 250 transactions. Its industry focus is strictly defined: ConAlliance advises exclusively on corporate acquisitions and divestitures in the global healthcare and life sciences industries. To this end, specialized teams combine traditional investment banking with deep expertise in the respective healthcare niches.